8VC’s Investment in Unlearn.AI

Imagine you have an incurable disease — maybe Alzheimer’s or multiple sclerosis. Though you might be willing to take a chance on science, you would nonetheless face a difficult decision in choosing whether to volunteer for a clinical trial. While you could potentially receive a better treatment, it’s equally likely that you would instead receive a placebo as part of the control arm of the study, used to verify the efficacy of the experimental drug. Despite bravely seeking to improve your life, you might end up as just a baseline comparator. That system doesn’t seem right.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
White Papers

Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease

Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.
How Digital Twins make it possible to design and run more efficient clinical trials with well-defined statistical properties.